Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine

Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine has been studied in 1 paper since 2026: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 31, 2026: “In vitro effects of synthetic immunotropic hexapeptides on CD63-CD16+CD62L+CD11b+ and CD63+CD16+CD62L+CD11b+ neutrophilic granulocytes in elderly and senile patients with chronic obstructive…”.

Intervention

1 paper studies it1 findingUpdated

More peptides

1 new paper in 30 daysSee all 1 papers on arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine

At a glance

The findings reach cells, none yet in people. 1 lab in 1 country.

Cells: a single group. Worms or flies, mice and humans: nothing yet.
  • 1 lab in 1 country
  • Cells1

What did studies of arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine find?

1

Studies of arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine measured one outcome, CD63+ neutrophil subsets.

CD63+ neutrophil subsets

downin human cells1

1 study
  1. Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine decreases CD63+ neutrophil subsets in human cells (chronic obstructive pulmonary disease).

    “After incubation with arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine, an increase in the neutrophil granulocyte subset CD63-CD16brightCD62LbrightCD11bbright was observed, while the CD63+CD16brightCD62LbrightCD11bbright and CD63+CD16brightCD62LdimCD11bbright neutrophil subsets were reduced.”

    Cellschronic obstructive pulmonary diseaseperipheral blood neutrophilic granulocytes

    In vitro effects of synthetic immunotropic hexapeptides on CD63-CD16+CD62L+CD11b+ and CD63+CD16+CD62L+CD11b+ neutrophilic granulocytes in elderly and senile patients with chronic obstructive pulmonary disease

    Russian Journal of Immunology

More on CD63+ neutrophil subsets

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months